Work

Neurofilament light chain as a biomarker to indicate early activation of cerebral disease in boys with adrenoleukodystrophy

Year: 2025

Type: article

Abstract: Adrenoleukodystrophy (ALD) is associated with disruption in very long chain fatty acid (VLCFA) processing due to a genetic mutation in the X-linked ABCD1 gene. The buildup of VLCFAs predisposes males to adrenal insufficiency (AI) and cerebral demyelination (cerebral ALD). If diagnosed early, these conditions can be treated effectively by hormone replacement and hematopoietic stem cell transplant, respectively. ALD is now included on the newborn screen panel in the majority of the United States. Thus far, there are no predictive tools to identify the development of early cerebral disease, necessitating frequent imaging surveillance with biannual MRIs starting at age 2 years through 12 years, then per annum for the remainder of the patient’s life. A bloodborne biomarker has been desirable to efficiently predict the onset of cerebral disease and reduce the healthcare burden on the family as well as healthcare expense. We prospectively measured plasma neurofilament light (NfL) chain levels in five boys with ALD who ultimately developed cerebral ALD. We describe that baseline plasma NfL levels can be established for boys with ALD and that an increase of 50% above baseline occurs at the time that cerebral disease develops. As far as we are aware, this is the first report highlighting that a bloodborne biomarker, plasma NfL, could potentially be used as a concomitant indicator of cerebral disease initiation, thus simplifying surveillance for cerebral ALD. Adrenoleukodystrophy (ALD) is an inherited disorder that affects how the body processes very long chain fatty acids (VLCFAs). In boys, this can lead to problems with the adrenal glands and damage to the brain. ALD is commonly found through newborn screening. Currently doctors must monitor boys with ALD using frequent blood tests and brain scans from age 2 and throughout life to screen for the development of disease in the brain. A blood test that could screen for disease development would be helpful for families and doctors as it would be easier to carry out than imaging. We find that the amount of a component in the blood called neurofilament light chain could be an indicator of the development of disease in the brain. This could provide an easier method to screen for the development of disease in the brain. Lund et al. assess whether levels of neurofilament light chain in the plasma can be used to monitor development of cerebral disease in people with adrenoleukodystrophy (ALD). Levels of plasma neurofilament light levels in the blood predicted cerebral disease onset in 5 boys with ALD.

Source: Communications Medicine

DOI: 10.1038/s43856-025-00915-6

Authors: Troy C. Lund, Ashish O. Gupta, Daniel J. Loes, David R. Nascene, Paul J. Orchard

Institutions: University of Minnesota, University of Minnesota Medical Center

Language: English

Topic: Metabolism and Genetic Disorders

Subfield: Clinical Biochemistry

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,690